The American Hospital Association has formally asked the FDA to adopt flexible, risk-based oversight for generative AI medical devices, and to clarify that certain generative AI administrative and decision-support tools should fall outside the agency’s regulatory oversight entirely, as the FDA’s comment period on its generative AI discussion paper closed October 19.
What the FDA’s Discussion Paper Actually Proposes
The FDA’s Center for Devices and Radiological Health released the discussion paper on August 18 to gather public input on how to regulate generative AI-enabled devices, explicitly stating the paper itself is not guidance and proposes no binding policy yet — a deliberately early step meant to shape eventual rules rather than issue them outright.
Why Hospitals Want a Lighter Touch
The AHA’s position reflects hospitals’ growing reliance on generative AI for tasks like clinical documentation, administrative triage and decision support that hospitals argue don’t rise to the level of traditional medical devices, since a heavy, uniform regulatory framework applied to every generative AI tool could slow adoption of systems hospitals say already improve efficiency without making direct diagnostic or treatment decisions.
Industry Isn’t Alone in Pushing Back
A U.S. Chamber of Commerce comment letter, also dated October 19, separately argued the FDA should gather significantly more input before setting rules specifically for agentic AI systems — tools that can take autonomous actions rather than simply generating text or recommendations — reflecting broader industry concern that regulators are moving to govern a technology that is still evolving faster than any rulebook can keep pace with.
The Competing View: Patients Need Protection Now
Patient-safety advocates and some physician groups have pushed in the opposite direction, pointing to a JAMA Network Open study finding that large language models tend to converge prematurely on a diagnosis when faced with clinical uncertainty, concluding these models are not yet ready for autonomous decision-making — a finding they argue justifies firmer, not lighter, oversight before generative AI tools see wider clinical deployment.
What the FDA Is Already Planning for 2027
Separate reporting indicates the FDA’s fiscal 2027 agenda includes draft recommendations specifically for generative AI conversational devices meant to treat mental health disorders, alongside guidance on AI-enabled robotic surgical systems, suggesting the agency intends to move forward with more specific rules regardless of how the current discussion-paper feedback is weighted.
What’s Next
Watch for the FDA to publish a formal summary of comments received under docket FDA-2026-N-7874, and watch whether the agency’s eventual 2027 guidance leans toward the AHA’s flexible, risk-based approach or toward the more cautious posture patient-safety advocates have pushed for.
Photo: Tima Miroshnichenko / PEXELS via Pexels
